ScreenerHero
ADPTAdaptive Biotechnologies Corp.
NAS · US · Healthcare · Diagnostics & Research · adaptivebiotech.com
25.15USD-1.33%Mkt Cap: 4.07B $P/E: —

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a su…

Industry Peers

Diagnostics & Research
Screen all
TMO
Thermo Fisher Scientific Inc.
$226.85BUSDP/E 33.1
DHR
Danaher Corporation
$151.78BUSDP/E 38.6
LONN
Lonza Group Ltd
$46.70BUSDP/E 37.9
NTRA
Natera, Inc.
$46.86BUSD
IDXX
IDEXX Laboratories, Inc.
$44.35BUSDP/E 39.5
A
Agilent Technologies, Inc.
$44.14BUSDP/E 31.4
IQV
IQVIA Holdings Inc
$41.03BUSDP/E 31.0
WAT
Waters Corporation
$40.83BUSDP/E 105.8
ILMN
Illumina, Inc.
$30.95BUSDP/E 38.2
MTD
Mettler-Toledo International, Inc.
$28.55BUSDP/E 32.1
LH
Labcorp Holdings Inc.
$26.80BUSDP/E 27.4
DGX
Quest Diagnostics Incorporated
$26.68BUSDP/E 25.6
GH
Guardant Health, Inc.
$21.92BUSD
MEDP
Medpace Holdings, Inc.
$16.98BUSDP/E 35.8
ERF
Eurofins Scientific SE
$13.64BUSDP/E 25.3
CRL
Charles River Laboratories International, Inc.
$13.84BUSD
RVTY
Revvity Inc. Common Stock
$13.33BUSDP/E 57.4
BIM
bioMerieux S.A.
$9.51BUSDP/E 19.0
QIA
Qiagen N.V.
$8.69BUSDP/E 22.8
TWST
Twist Bioscience Corp.
$8.93BUSD

Key Statistics

Company
Market Cap4.07B $
Enterprise Value4.13B $
Revenue (TTM)308.08M $
Gross Profit205.62M $
Net Income (TTM)-59.50M $
Revenue/Share1.984 USD
Last Price25.15 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees624
CountryUS
SectorHealthcare
IndustryDiagnostics & Research
ISINUS00650F1093
Valuation
P/E (Trailing)—
P/E (Forward)-137.71
PEG—
EV/EBITDA-193.84
EV/Revenue13.42
P/S13.18
P/B28.33
EPS (TTM)-0.40
EPS (Forward)-0.18
52W Range
11.8593% of range26.16
52W High26.16 USD
52W Low11.85 USD
Profitability
Gross Margin74.24%
Oper. Margin-22.04%
EBITDA Margin-6.92%
Profit Margin-21.48%
ROE-27.19%
ROA-11.60%
Growth
Revenue Growth21.50%
Earnings Growth—
Cash Flow & Leverage
Operating CF-45.99M $
CapEx (TTM)2.96M $
FCF Margin6.16%
FCF Yield0.47%
Net Debt66.24M $
Net Debt/EBITDA-3.11
Balance Sheet
Debt/Equity0.36
Current Ratio4.79
Quick Ratio4.51
Book Value/Sh0.8980 USD
Cash/Share2.157 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.5 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)25.07 USD
Upside (mean)-0.3%
Target Range21.00 USD – 28.00 USD
$21.00-0.3% to mean$28.00
# Analysts7
Ownership
Shares Out.159.60M
Float125.37M
Insiders1.39%
Institutions99.26%
Short Interest
Short Ratio4.4d
Short % Float9.93%
Short % Out.7.85%
Shares Short12.49M
Short (prev mo.)11.35M
Technical
SMA 5021.83 (+15.2%)
SMA 20017.13 (+46.8%)
Beta2.09
S&P 52W Chg18.16%
Avg Vol (30d)2.60M
Avg Vol (10d)2.15M
Technical Indicators
RSI (14)63.9
MACD1.2286
MACD Signal1.3164
MACD Hist.-0.0878
BB Upper26.36 USD
BB Middle23.86 USD
BB Lower21.36 USD
BB Width20.95%
ATR (14)1.273 USD
Vol Ratio (20d)0.82x